Clinical Trial

BaseLaunch Announces the Addition of Takeda as New Pharmaceutical Partner to its Biotech Venture Incubator

Takeda will join five existing leading pharma company partners supporting and funding promising drug development startups.BASEL, Switzerland, Dec. 16, 2025…

2 months ago

BaseLaunch Announces the Addition of Takeda as New Pharmaceutical Partner to its Biotech Venture Incubator

Takeda will join five existing leading pharma company partners supporting and funding promising drug development startups.BASEL, Switzerland, Dec. 16, 2025…

2 months ago

PhaseV Closes 2025 with Record Growth, Supporting Biopharma’s Shift from AI Pilots to Full-Scale Execution

Company Enters 2026 Positioned for Wide-Scale Deployment, Fueled by $50M Series A, 40+ Global Sponsors, and Measurable ROIBOSTON, Dec. 16,…

2 months ago

PhaseV Closes 2025 with Record Growth, Supporting Biopharma’s Shift from AI Pilots to Full-Scale Execution

Company Enters 2026 Positioned for Wide-Scale Deployment, Fueled by $50M Series A, 40+ Global Sponsors, and Measurable ROIBOSTON, Dec. 16,…

2 months ago

IDC MarketScape: ZS named a Leader in life sciences R&D AI in clinical trials

EVANSTON, Ill., Dec. 16, 2025 /PRNewswire/ -- ZS has been named a Leader in the inaugural IDC MarketScape: Worldwide Life…

2 months ago

IDC MarketScape: ZS named a Leader in life sciences R&D AI in clinical trials

EVANSTON, Ill., Dec. 16, 2025 /PRNewswire/ -- ZS has been named a Leader in the inaugural IDC MarketScape: Worldwide Life…

2 months ago

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

Vancouver, Canada, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a…

2 months ago

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

Vancouver, Canada, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a…

2 months ago

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

Vancouver, Canada, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a…

2 months ago

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer

Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full…

2 months ago